2023 - Research.com Medicine in Denmark Leader Award
His primary areas of study are Radiation therapy, Internal medicine, Oncology, Pathology and Surgery. Jens Overgaard has researched Radiation therapy in several fields, including Breast cancer, Carcinoma and Nuclear medicine. His study looks at the relationship between Breast cancer and fields such as Chemotherapy, as well as how they intersect with chemical problems.
His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Colorectal cancer and Adenoid cystic carcinoma. His work carried out in the field of Oncology brings together such families of science as Odds ratio, Cell, Clinical trial, Randomized controlled trial and Hazard ratio. Jens Overgaard has included themes like Cancer research, Radiosensitivity, Hypoxia, Hyperthermia and In vivo in his Pathology study.
His main research concerns Internal medicine, Radiation therapy, Oncology, Pathology and Surgery. His work on Endocrinology expands to the thematically related Internal medicine. Jens Overgaard combines subjects such as Carcinoma, Randomized controlled trial and Nuclear medicine with his study of Radiation therapy.
The study incorporates disciplines such as Head and neck squamous-cell carcinoma, Head and neck, Basal cell, Hazard ratio and Cohort in addition to Oncology. His study looks at the intersection of Pathology and topics like In vivo with Mammary carcinoma. His Surgery study frequently draws connections to adjacent fields such as Urology.
His scientific interests lie mostly in Internal medicine, Oncology, Radiation therapy, Head and neck cancer and DAHANCA. His study in Internal medicine concentrates on Cancer, Breast cancer, Cohort, Head and neck squamous-cell carcinoma and Nimorazole. His studies deal with areas such as Carcinoma, Clinical endpoint, Randomized controlled trial, Pathology and Hazard ratio as well as Oncology.
The Radiation therapy study combines topics in areas such as Clinical trial, Cohort study and Hypoxia. His DAHANCA study combines topics in areas such as Dose fractionation, Head and neck, Logistic regression and Quality assurance. His work on Prospective cohort study as part of his general Surgery study is frequently connected to In patient, thereby bridging the divide between different branches of science.
His primary scientific interests are in Internal medicine, Radiation therapy, Oncology, DAHANCA and Head and neck cancer. Much of his study explores Internal medicine relationship to Surgery. His biological study spans a wide range of topics, including Absolute risk reduction, Clinical trial, Medical physics and Carcinoma.
His Oncology study integrates concerns from other disciplines, such as Head and neck squamous-cell carcinoma, Pathology, Clinical endpoint, Hazard ratio and Breast cancer. His DAHANCA research is multidisciplinary, incorporating elements of Glottic Squamous Cell Carcinoma, Laryngectomy and Nimorazole. His Head and neck cancer research is multidisciplinary, incorporating perspectives in Prospective data, Larynx and Quality assurance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe;R. Abe;K. Enomoto;K. Kikuchi.
The Lancet (2005)
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
Marie Overgaard;Per S. Hansen;Jens Overgaard;Carsten Rose.
The New England Journal of Medicine (1997)
Postoperative radiotherapy in high-risk postmenopausal breast- cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
Marie Overgaard;Maj-Britt Jensen;Jens Overgaard;Per S Hansen.
The Lancet (1999)
Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
Marianne Nordsmark;Marie Overgaard;Jens Overgaard.
Radiotherapy and Oncology (1996)
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Jean Bourhis;Jens Overgaard;Helene Audry;Kian K. Ang.
The Lancet (2006)
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
Marianne Nordsmark;Søren M. Bentzen;Volker Rudat;David Brizel.
Radiotherapy and Oncology (2005)
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
Jens Overgaard;Hanne Sand Hansen;Lena Specht;Marie Overgaard.
The Lancet (2003)
Hypoxic Radiosensitization: Adored and Ignored
Journal of Clinical Oncology (2007)
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
Jens Overgaard;Hanne Sand Hansen;Marie Overgaard;Lars Bastholt.
Radiotherapy and Oncology (1998)
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
Marianne Kyndi;Flemming B. Sørensen;Helle Knudsen;Marie Overgaard.
Journal of Clinical Oncology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: